Dow and BioLogiQ are collaborating to evaluate potential synergies between BioLogiQ’s novel NuPlastiQ® BioPolymer, a thermoplastic plant-based resin, and Dow’s industry-leading polyethylene resin portfolio, in an effort to explore enhanced sustainable plastic options.
Enabling More Plant-Based Plastic Products
Dow and BioLogiQ will work together to test and consider potential applications that incorporate biobased resins with polyethylene, in the hopes of enabling more plant-based plastic products. BioLogiQ, a seven-year-old startup based in Idaho Falls, Idaho that’s committed to creating plastics from renewable resources, will utilize Dow’s industry-leading research and development, as well as the company’s extensive plastic resin sales and distribution network, to determine if they can successfully leverage plant-based plastics.
“As a science-driven company, Dow is excited by the technical and environmental advantages that could be achieved by combining NuPlastiQ with Dow’s industry-leading polyethylene,” stated Tim Boven, recycling commercial director at Dow. “We are looking forward to learning more about NuPlastiQ, and hope the collaboration will help us determine how these product combinations can benefit the market needs for the future.”
Deliver Breakthrough Sustainable Chemistry Innovations
Dow’s commitment and mission to deliver breakthrough sustainable chemistry innovations that advance the well-being of humanity directly aligns with BioLogiQ’s goal of discovering more sustainable solutions to plastics.
“Our mission at BioLogiQ is to provide a way to create plastic products made from renewable resources,” explained Brad LaPray, founder and president of BioLogiQ. “This evaluation will help us determine if there is an opportunity for Dow and BioLogiQ to work together in the future to offer new applications to our customers.”
The evaluation will help determine if NuPlastiQ is a potential fit with Dow’s business from performance, bio-based and commercial viability perspectives. During the next year, Dow and BioLogiQ will perform evaluations at Dow’s Pack Studios Development Center in Freeport, Texas and engage brands, research institutes and associations to evaluate the range of benefits from a combined offering.